Our Grants

CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.

Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.

All CIRM Grants

Search Filters »

Institution Researcher name Grant Type Grant Title Award Value
University of California, Los Angeles Dr. Yong Kim Basic Biology II Novel Mechanism in Self-Renewal/Differentiation of Human Embryonic Stem Cells $1,259,371
University of California, San Diego Dr. Kun-Liang Guan Basic Biology II The function of YAP in human embryonic stem cells $1,245,693
Stanford University Dr. Aaron J Hsueh Basic Biology II Maturation of Human Oocytes for SCNT and Embryonic Stem Cell Derivation $1,309,018
University of California, San Francisco Dr. John L Rubenstein Basic Biology II MGE Enhancers to Select for Interneuron Precursors Produced from Human ES Cells $1,387,800
Sanford Burnham Prebys Medical Discovery Institute Dr. Huei-sheng Vincent Chen Basic Biology II Endothelial cells and ion channel maturation of human stem cell-derived cardiomyocytes $1,587,610
University of California, Irvine Dr. Aileen J Anderson Basic Biology II Role of the microenvironment in human iPS and NSC fate and tumorigenesis $1,256,194
Stanford University Dr. Steven Edward Artandi Basic Biology II Self-renewal and senescence in iPS cells derived from patients with a stem cell disease $931,285
Salk Institute for Biological Studies Ronald Mark Evans Basic Biology II Molecular Characterization and Functional Exploration of Nuclear Receptors in hiPSCs $1,712,880
Calimmune, Inc. Geoff Symonds Disease Team Research I GENE-MODIFIED HEMATOPOIETIC STEM/PROGENITOR CELL BASED THERAPY FOR HIV DISEASE $8,278,722
Stanford University Dr. Gary Steinberg Disease Team Research I Embryonic-Derived Neural Stem Cells for Treatment of Motor Sequelae following Sub-cortical Stroke $17,244,851
University of California, San Diego Dr. Lawrence S. B. Goldstein Disease Team Research I Stem Cell-Derived Astrocyte Precursor Transplants in Amyotrophic Lateral Sclerosis $5,694,308
University of California, Los Angeles Dr. Donald B. Kohn Disease Team Research I Stem Cell Gene Therapy for Sickle Cell Disease $8,833,695
University of California, Los Angeles Dr. Irvin SY Chen Disease Team Research I HPSC based therapy for HIV disease using RNAi to CCR5. $9,905,604
ViaCyte, Inc. Allan Robins Disease Team Research I Cell Therapy for Diabetes $0
Cedars-Sinai Medical Center Eduardo Marbán Disease Team Research I Autologous cardiac-derived cells for advanced ischemic cardiomyopathy $5,560,232
University of California, San Francisco Dr. Mitchel S Berger Disease Team Research I Stem Cell-Mediated Oncocidal Gene Therapy of Glioblastoma (GBM) $6,214,914
City of Hope, Beckman Research Institute Prof. Karen S Aboody M.D. Disease Team Research I Stem Cell-mediated Therapy for High-grade Glioma: Toward Phase I-II Clinical Trials $17,890,623
Stanford University Dr. Alfred T Lane Disease Team Research I iPS Cell-Based Treatment of Dominant Dystrophic Epidermolysis Bullosa $11,039,208
Stanford University Professor Irving L Weissman MD Disease Team Research I Development of Therapeutic Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells $18,759,276
University of California, Los Angeles Dr. Dennis J Slamon Disease Team Research I Therapeutic Opportunities To Target Tumor Initiating Cells in Solid Tumors $19,979,660
City of Hope, Beckman Research Institute Prof. John A. Zaia Disease Team Research I ZINC FINGER NUCLEASE-BASED STEM CELL THERAPY FOR AIDS $14,536,969
University of Southern California Mark Salman Humayun Disease Team Research I Stem cell based treatment strategy for Age-related Macular Degeneration (AMD) $18,904,916
University of California, San Diego Dr. Dennis A Carson Disease Team Research I Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT) $19,999,826
University of California, San Diego Dr. Gene Wei-Ming Yeo Basic Biology I RNA Binding Protein-mediated Post-transcriptional Networks Regulating HPSC Pluripotency $1,308,901
University of California, San Diego Karl H. Willert Basic Biology I WNT signaling and the control of cell fate decisions in human pluripotent stem cells. $1,329,298
University of California, Davis Dr. Min Zhao Basic Biology I Directing migration of human stem cells with electric fields $816,228
University of California, Los Angeles Dr. Michael A. Teitell Basic Biology I Mitochondrial Metabolism in hESC and hiPSC Differentiation, Reprogramming, and Cancer $1,323,029
University of Southern California Dr. Martin Pera Basic Biology I The stem cell microenvironment in the maintenance of pluripotency and reprogramming $1,325,723
Stanford University Dr. Julien Sage Basic Biology I The retinoblastoma (RB) gene family in cellular reprogramming $1,357,085
Stanford University Dr. Susan K McConnell Basic Biology I Identification and characterization of human ES-derived DA neuronal subtypes $1,404,853
University of California, Los Angeles Bennett G Novitch Basic Biology I Molecular Characterization of hESC and hIPSC-Derived Spinal Motor Neurons $1,228,278
University of California, Los Angeles Dr. Robb Maclellan Dr. Basic Biology I Human Cardiovascular Progenitors, their Niches and Control of Self-renewal and Cell Fate $917,667
University of Southern California Dr. Wange Lu Basic Biology I Defining the molecular mechanisms of somatic cell reprogramming $1,365,580
Stanford University Professor Helen M. Blau PhD Basic Biology I Molecular Mechanisms of Reprogramming towards Pluripotency $1,408,332
University of California, Los Angeles Dr. Luisa Iruela-Arispe Basic Biology I Molecular Characterization and Functional Exploration of Hemogenic Endothelium $1,371,477
Jackson Labs Pali G. Kaur Early Translational I Mouse Models for Stem Cell Therapeutic Development $3,759,134
Gladstone Institutes, J. David Dr. Warner C Greene Early Translational I Maximizing the Safety of Induced Pluripotent Stem Cells as an Infusion Therapy: Limiting the Mutagenic Threat of Retroelement Retrotransposition during iPSC Generation, Expansion and Differentiation $1,280,001
Scripps Research Institute Dr. Martin Friedlander Early Translational I Autologous Retinal Pigmented Epithelial Cells Derived from Induced Pluripotent Stem Cells for the Treatment of Atrophic Age Related Macular Degeneration $5,806,321
University of California, Los Angeles Dr. Gabriel H. Travis Early Translational I Development of a Stem Cell-based Transplantation Strategy for Treating Age-related Macular Degeneration $5,487,136
Scripps Research Institute Dr. Jeanne F Loring Early Translational I Ensuring the safety of cell therapy: a quality control pipeline for cell purification and validation $5,830,771
ViaCyte, Inc. Dr. Olivia G. Kelly Early Translational I Methods for detection and elimination of residual human embryonic stem cells in a differentiated cell product $5,405,397
Scripps Health Dr. Darryl D. D’Lima Early Translational I Stem Cell-Based Therapy for Cartilage Regeneration and Osteoarthritis $3,118,431
University of California, Irvine Dr. Frank LaFerla Early Translational I Neural Stem Cells as a Developmental Candidate to Treat Alzheimer Disease $3,599,997
University of California, Davis Dr Jan A Nolta Early Translational I Sustained siRNA production from human MSC to treat Huntingtons Disease and other neurodegenerative disorders $2,615,674
University of California, San Diego Dr Yang Xu Early Translational I Developing induced pluripotent stem cells into human therapeutics and disease models $5,165,028
Parkinson’s Institute Mr. James “Bill” William Langston Mr. Early Translational I Using patient-specific iPSC derived dopaminergic neurons to overcome a major bottleneck in Parkinson’s disease research and drug discovery $3,698,646
University of California, Berkeley Ellen Robey Transplantation Immunology Human Immune System Mouse models as preclinical platforms for stem cell derived grafts $1,005,605
Scripps Research Institute Dr. Nicholas R.J. Gascoigne Transplantation Immunology Role of Innate Immunity in hematopoeitic stem cell-mediated allograft tolerance $1,705,554
Stanford University Kenneth Weinberg Transplantation Immunology Engineered immune tolerance by Stem Cell-derived thymic regeneration $1,271,729
University of California, Berkeley Dr. David H Raulet Transplantation Immunology Inactivating NK cell reactivity to facilitate transplantation of stem cell derived tissue $952,896
1 2 3 4 5 6 7 8 9 10 11 … 32

How to Apply

Learn More

Explore CIRM-Funded Clinical Trials

Learn More

Managing Your Grant

Learn More

See our Active Awards Portfolio

Learn More